American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 5 , Pages 309-315 , September 2007

BMS-275183–induced gene expression patterns in head and neck carcinoma

  • George H. Yoo, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Corresponding Author InformationCorresponding author. Department of Otolaryngology-Head and Neck Surgery, Wayne State University, 4201 St. Antoine, 5 E University Health Center, Detroit, MI 48201, USA. Tel.: +1 313 745 4336; fax: +1 313 577 8555.
    • ,
  • Vivian R. Tran, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Lori A. Lemonnier, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Waleed H. Ezzat, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Geetha Subramanian, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Marie P. Piechocki, PhD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • John F. Ensley, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Division of Hematology/Oncology, Department of Medicine, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Fulvio Lonardo, MD

      Affiliations

    • Department of Pathology, Wayne State University, Detroit, MI, USA
    • ,
  • Harold Kim, MD

      Affiliations

    • Department of Radiation Oncology, Wayne State University, Detroit, MI, USA
    • ,
  • Ho-Sheng Lin, MD

      Affiliations

    • Department of Otolaryngology-Head and Neck Surgery, Wayne State University and Karmanos Cancer Institute, Detroit, MI, USA
    • Department of Surgery, John D. Dingell VA Medical Center, Detroit, MI, USA

Received 27 July 2006

References 

  1. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310–1317
  2. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16(4):1318–1324
  3. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98
  4. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91(24):2081–2086
  5. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–1690
  6. Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst. 1996;88(13):890–899
  7. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952
  8. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944
  9. Kish JA, Benedetti JK, Balcerzak SP, et al. Feasibility trial of postoperative radiotherapy and cisplatin followed by three courses of 5-FU and cisplatin in patients with resected head and neck cancer: a Southwest Oncology Group study. Cancer J Sci Am. 1999;5(5):307–311
  10. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer. 2000;1(1):32–40discussion 41-2
  11. Belani CP. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Oncology (Huntingt). 1997;11(8 Suppl 8):42–45
  12. Kaye SB, Vasey PA. Docetaxel in ovarian cancer: phase III perspectives and future development. Semin Oncol. 2002;29(3 Suppl 12):22–27
  13. Posner MR, Glisson B, Frenette G, et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2001;19(4):1096–1104
  14. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19(2):289–298
  15. Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol. 1999;17(11):3503–3511
  16. Colevas AD, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol. 1998;16(4):1331–1339
  17. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs. 2001;12(Suppl 1):S21–S24
  18. Schrijvers D, Vermorken JB. Role of taxoids in head and neck cancer. Oncologist. 2000;5(3):199–208
  19. Luck HJ, Scholz U, Kuhnle H, et al. UFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer. Oncology (Williston Park). 1999;13(7 Suppl 3):74–76
  20. Mastalerz H, Cook D, Fairchild CR, et al. The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem. 2003;11(20):4315–4323
  21. Rose WC, Long BH, Fairchild CR, et al. Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res. 2001;7(7):2016–2021
  22. Rose WC, Wild R. Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts. Clin Cancer Res. 2004;10(21):7413–7417
  23. Broker LE, de Vos FY, van Groeningen CJ, et al. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res. 2006;12(6):1760–1767
  24. Yeudall WA, Jakus J, Ensley JF, et al. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog. 1997;18(2):89–96
  25. Yoo GH, Piechocki MP, Ensley JF, et al. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res. 2002;8(12):3910–3921
  26. Kamen BA, Rubin E, Aisner J, et al. High-time chemotherapy or high time for low dose. J Clin Oncol. 2000;18(16):2935–2937
  27. Zanelli GD, Quaia M, Robieux I, et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer. 1997;33(3):486–492
  28. Liebmann JE, Cook JA, Lipschultz C, et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. 1993;68(6):1104–1109
  29. Belani CP. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Semin Oncol. 2002;29(3 Suppl 12):4–9
  30. Malingre MM, Beijnen JH, Schellens JH. Oral delivery of taxanes. Invest New Drugs. 2001;19(2):155–162
  31. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031–2035
  32. van Asperen J, van Tellingen O, Sparreboom A, et al. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer. 1997;76(9):1181–1183
  33. van Asperen J, van Tellingen O, van der Valk MA, et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin Cancer Res. 1998;4(10):2293–2297
  34. Meerum J, Terwogt M, Malingre MM, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res. 1999;5(11):3379–3384
  35. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des. 2001;7(13):1251–1257
  36. Polizzi D, Pratesi G, Monestiroli S, et al. Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res. 2000;6(5):2070–2074
  37. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer. 1999;83(2):151–156
  38. Chadebech P, Truchet I, Brichese L, et al. Up-regulation of cdc2 protein during paclitaxel-induced apoptosis. Int J Cancer. 2000;87(6):779–786
  39. Giannakakou P, Robey R, Fojo T, et al. Low concentrations of paclitaxel induce cell type–dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001;20(29):3806–3813
  40. Papadimitrakopoulou VA, Shin DM, Hong WK. Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. Cancer Metastasis Rev. 1996;15(1):53–76
  41. Tsai CM, Yu D, Chang KT, et al. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J Natl Cancer Inst. 1995;87(9):682–684
  42. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000;22(7):673–680
  43. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000;6(12):4885–4892
  44. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58(13):2825–2831
  45. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res. 2000;254(1):110–119
  46. Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275(20):14838–14845
  47. Okano J, Rustgi AK. Paclitaxel induces prolonged activation of the Ras/MEK/ERK pathway independently of activating the programmed cell death machinery. J Biol Chem. 2001;276(22):19555–19564
  48. Lieu CH, Liu CC, Yu TH, et al. Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ. 1998;9(9):767–776
  49. Seidman R, Gitelman I, Sagi O, et al. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res. 2001;268(1):84–92
  50. Bacus SS, Gudkov AV, Lowe M, et al. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001;20(2):147–155
  51. Wang LG, Liu XM, Kreis W, et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44(5):355–361
  52. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res. 1997;57(2):229–233
  53. Berchem GJ, Bosseler M, Mine N, et al. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res. 1999;19(1A):535–540
  54. Pucci B, Bellincampi L, Tafani M, et al. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. Exp Cell Res. 1999;252(1):134–143
  55. Roth W, Wagenknecht B, Grimmel C, et al. Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. Br J Cancer. 1998;77(3):404–411
  56. Nimmanapalli R, Perkins CL, Orlando M, et al. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001;61(2):759–763
  57. Odoux C, Albers A, Amoscato AA, et al. TRAIL, FasL and a blocking anti-DR5 antibody augment paclitaxel-induced apoptosis in human non-small-cell lung cancer. Int J Cancer. 2002;97(4):458–465
  58. Piechocki MP, Lonardo F, Ensley JF, et al. Anticancer activity of docetaxel in murine salivary gland carcinoma. Clin Cancer Res. 2002;8(3):870–877

☆ This work was supported by the National Institutes of Health/NIDCR, Bethesda, MD (R21 DE014878).

PII: S0196-0709(06)00226-2

doi: 10.1016/j.amjoto.2006.10.001

American Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume 28, Issue 5 , Pages 309-315 , September 2007

Article Tools

* Image Usage & Resolution